Steven Bupp, MD
Psychiatry · Tucson, AZNPI 1780659029
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $332 of the $438 with a category attached, or 75.9%. 9 manufacturers reported payments, led by Johnson & Johnson at 37.6% of the total. Reporting peaked in 2019 at $353 and has fallen 92.3% since, to $27 in 2024.
Across 30 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$165
- AbbVie$84
- Otsuka America Pharmaceutical, Inc.$56
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
- E.r. Squibb & Sons, L.L.C.$27
- Indivior Inc.$21
- plus $38 from 3 others
Across 139 payments — averaging $3243.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$223K
- Alkermes, Inc.$128K
- Janssen Research & Development, LLC$41K
- Boehringer Ingelheim International GmbH$37K
- Takeda Pharmaceuticals U.S.A., Inc.$22K
What the payments were for
- Food & beverage$33276%
- Education$10624%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $165 |
| AbbVie | 5 | $84 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $47 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Indivior Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $9 |
How this compares
$438 in reported general payments places this provider in the 60th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 52 | $36,106 |
| AdderallDextroamphetamine/Amphetamine | 24 | $15,909 |
| Naltrexone Hcl | 56 | $8,279 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 223 | $5,422 |
| Clozapine | 50 | $5,125 |
| Quetiapine Fumarate | 250 | $4,693 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 57 | $4,641 |
| Lamotrigine | 277 | $3,870 |
| Duloxetine Hcl | 187 | $3,746 |
| Methylphenidate Hcl | 52 | $3,320 |
| Bupropion XlBupropion Hcl | 89 | $3,283 |
| Aripiprazole | 22 | $3,079 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 84 | $3,075 |
| Clonazepam | 289 | $3,015 |
| Bupropion Hcl SrBupropion Hcl | 135 | $3,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall | $9 | $52,01576 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $16 | $1,38126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Tucson
- Marlene FreemanTucson$59K
- Francisco MorenoTucson$40K
- Jennifer TreuschTucson$29K
- Samantha FrembgenTucson$9K
- Peter KowalskiTucson$8K
- Stephen StreitfeldTucson$6K
- Richard BarnesTucson$5K
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.